| Project/Area Number |
23591955
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
HIROSE Mayumi 金沢大学, がん進展制御研究所, 研究員 (00353524)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MINAMOTO Toshinari 金沢大学, がん進展制御研究所, 教授 (50239323)
KAWAKAMI Kazuyuki 東京女子医科大学, 医学部, 准教授 (00293358)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 消化器がん / 大腸がん / すい臓がん / GSK3beta / Drug repositioning / 医薬品 / 細胞運動 / 細胞増殖 / GSK3β / 抗がん剤 / 薬剤スクリーニング |
|---|
| Research Abstract |
GSK3beta is a serine/threonine protein kinase that implicated in diseases including cancer. To date, there are no clinical trial reports describing the use of specific GSK3beta inhibitors for cancer, while our results of basic research have identified GSK3beta as a tumor promoter and druggable target for cancer treatment. Several drugs prescribed for diseases other than cancer were shown to have an inhibitory effect against GSK3beta. Here we show that inhibition of GSK3beta by using these drugs, alone or in combination, compromises survival, proliferation, migration and invasion of human colon and pancreatic cancer cells. We also show that the combination of GSK3beta-inhibiting drugs is more effective than the single agent treatment against both types of cancer cell lines. Our findings warrant further investigation and preclinical study on the effective combination of GSK3beta-inhibiting drugs and that with chemotherapeutic agents for treatment of gastrointestinal cancer.
|
